Tacrolimus

Tacrolimus 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Kidney Transplant Rejection、Acute Leukemia、Acute Lymphoblastic Leukemia、Acute Myeloid Leukemia。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Tacrolimus 研究

• Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

  I 期招募中美国NCT06996119

• High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

  II 期招募中美国NCT06345495

• Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

  II 期 / III 期招募中美国澳大利亚Brazil中国NCT07204275

• Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

  II 期招募中美国NCT04370301

• A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

  III 期招募中美国Argentina比利时法国NCT04877288

• Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

  II 期招募中RussiaNCT07238712

• Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years

  II 期招募中法国NCT06646497

• Study of Tacrolimus Melt-Dose® for Lung Transplant Patients

  不适用招募中西班牙NCT07042035

• Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease

  不适用招募中中国NCT07843381

• Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies

  III 期招募中法国NCT05385432

• 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

  I 期招募中美国NCT06287944

• A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

  II 期 / III 期招募中美国Argentina澳大利亚比利时NCT07412470

• Advancing Transplantation Outcomes in Children

  II 期招募中美国加拿大NCT06055608

• Belatacept in Heart Transplantation

  II 期招募中美国NCT06478017

• Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

  II 期招募中美国NCT03970096

• CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients

  II 期 / III 期招募中美国NCT03769298

• Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations

  IV 期招募中加拿大NCT05089604

• Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

  I 期 / II 期招募中美国NCT03500731

• Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)

  IV 期招募中法国NCT06354179

• Islet Transplantation in Type 1 Diabetic Kidney Allograft

  II 期招募中美国NCT01241864

• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

  II 期招募中美国NCT07138898

• Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

  II 期招募中美国NCT06807606

• Belatacept in De Novo Heart Transplantation

  II 期招募中美国NCT04477629

• TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation

  不适用招募中法国NCT06829719

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。